06/09 Taiwan BIO Weekly
2026-06-09 |
| Taiwan BIO Weekly |
| Elixiron Immunotherapeutics reveals highlights from interim Phase II Alzheimer's trial data 5 June, 2026 Elixiron Immunotherapeutics (TW: 7871) announced interim Phase II clinical trial data for its next-generation Alzheimer's drug candidate Enrupatinib (EI-1071). The results show that EI-1071 demonstrates a favorable safety and tolerability profile, and signals from neuroimaging and exploratory biomarkers suggest potential effects in regulating neuroinflammation and slowing disease progression. The company noted that interim results are encouraging and further reinforce the potential of targeting neuroinflammation as a therapeutic strategy for Alzheimer's disease, and given the lack of effective disease-modifying treatments, neuroinflammation may represent a promising new avenue of research. More... (in Chinese) |
| Genomics BioSci & Tech partners with ATRI and Wang Choice Digital Biotech for pet diagnostics push 4 June, 2026 Genomics BioSci & Tech (TW: 4195) has secured a non-exclusive license from Taiwan's Agricultural Technology Research Institute (ATRI) for canine and feline hereditary disease testing technology, marking its entry into the pet diagnostics market. To accelerate commercialization, Genomics BioSci & Tech has formed a strategic partnership with Wang Choice Digital Biotech, where ATRI will provide the core technology, Genomics BioSci & Tech will develop and operate the testing services, and Wang Choice Digital Biotech will lead marketing, channel development, and after-sales support. More... (in Chinese) |
| KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market Press release 3 June, 2026 Brain Navi Biotechnology announced that its KrystoLens, the single-use neuro-endoscope, has officially received certification from the Taiwan Food and Drug Administration (TFDA), marking an important milestone in the company's development in medical imaging and endoscopic applications. Following its recognition at the 22nd National Innovation Award earlier this year, KrystoLens has once again gained attention for its product innovation and clinical potential. The TFDA certification confirms that the product complies with Taiwan's medical device regulatory requirements and paves the way for its formal introduction into the local healthcare market. More... |
| TWi Biotechnology advances AC-1101 to target global alopecia areata market 3 June, 2026 TWi Biotechnology (TW: 6610) has submitted an application to the Taiwan FDA to initiate a Phase IIa clinical trial for its investigational drug AC-1101, which is being developed for the treatment of alopecia areata (AA). This development comes as the company's core asset, AC-203, is currently undergoing global Phase II/III clinical trials, with topline (unblinded) results expected in the fourth quarter of 2026. The progress highlights TWi Biotechnology's continued expansion beyond rare diseases, while also opening a new growth driver and advancing its position toward becoming a leader in dermatology and immune-mediated skin diseases. More... (in Chinese) |
| Lumosa Therapeutics stroke drug LT3001 receives additional US patent 2 June, 2026 Lumosa Therapeutics (TW: 6535) announced that its US patent for the administration method of its innovative ischemic stroke drug LT3001 has been granted, extending the patent protection period to 2042. This further strengthens the product's legal protection after market launch and enhances its international licensing value. The company stated that LT3001 has dual potential as both a thrombolytic and neuroprotective therapy, specifically designed for ischemic stroke. The drug is protected by a comprehensive patent portfolio covering the compound, formulation, and administration method. More... (in Chinese) |
| Jensen Huang showcases AI drug development at GTC, AnHorn Biopharma's AH-001 draws attention 1 June, 2026 AnHorn Biopharma announced that at the global AI technology event GTC 2026, Jensen Huang again highlighted the latest achievements in applying artificial intelligence to drug development in the opening video, with the company's AI-driven drug design and development model drawing attention and underscoring Taiwan's growing international presence in AI-enabled drug discovery. AnHorn Biopharma focuses on AI-driven novel drug development, with its core competitive strength built on a protein degradation technology platform. More... (in Chinese) |
| BioMab partners with Vietnam's Vinmec Hospital on NK cell clinical development 1 June, 2026 BioMab has announced a strategic clinical collaboration with Vinmec International Hospital in Vietnam. The partnership will leverage BioMab's proprietary expanded natural killer cell ex vivo culture kit to support the clinical development and testing of natural killer cell therapies. The two parties will also utilize organoid models to explore innovative translational applications, supporting the development of next-generation immunotherapies for cancer and other diseases. More... (in Chinese) |
| TaiMed Biologics' HIV drug Trogarzo nears Taiwan launch 1 June, 2026 TaiMed Biologics (TW: 4147) announced on the 1st of June that its partner Orient Europharma (TW: 4120) has received a product name approval letter issued by the Taiwan FDA. The official Chinese and English names for Trogarzo have now been approved, marking the final step before obtaining marketing authorization and commercial launch. TaiMed stated that Orient Europharma will proceed to submit the required documentation, including the package insert and related materials, in accordance with regulations. Once the TFDA issues the official marketing approval, Trogarzo can be launched and promoted in Taiwan, providing a new treatment option for patients with multidrug-resistant HIV. More... (in Chinese) |
| Aprinoia Therapeutics developing imaging + AI ecosystem to treat neurodegenerative diseases 1 June, 2026 Aprinoia Therapeutics is a Taiwan-founded biotech company developing an integrated 'imaging + drug + device' ecosystem for neurodegenerative diseases. Co-founded by Jang Ming-Kuei and Japan's QST researcher Makoto Higuchi, the company focuses on PET imaging agents and brain-penetrant molecular probes that enable visualization and staging of disease-related protein pathology. With R&D operations across Japan, China, Singapore, and the US, Aprinoia Therapeutics' lead diagnostic programs are advancing through late-stage clinical development, positioning the company as a key enabler of earlier Alzheimer’s detection and precision treatment strategies, supported by unique brain pathology resources and collaborations with global pharmaceutical partners such as Biogen. More... (in Chinese) |
| Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview Press release 1 June, 2026 Jyong Biotech Ltd. (Nasdaq: MENS) a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today highlighted a strategic vision detailed by its founder and Chief Executive Officer, Ms. Fu-Feng Kuo, in a recently published live interview with PharmaBoardroom, a UK-based platform providing global intelligence for the healthcare and life sciences industries. More... |
| Foresee Pharmaceuticals' application for new breast cancer indication accepted for review by China's NMPA 31 May, 2026 Foresee Pharmaceuticals (TW: 6576) announced that its marketing authorization application in China for an additional indication of its leuprolide injectable emulsion for the treatment of premenopausal breast cancer has been accepted by the China's National Medical Products Administration (NMPA) and has entered substantive review. The review process is reasonably expected to take approximately 18-24 months. More... (in Chinese) |
| NVIDIA, Foxconn and Taiwan Medical Centers Bring Agentic and Physical AI to 'Healthy Taiwan' Press release 31 May, 2026 NVIDIA today announced that Foxconn and Taiwan's leading medical centers are deploying NVIDIA-powered special agent workforces to scale the region's transition to AI?driven health systems. With one of the world's fastest-aging populations, Taiwan faces mounting pressure on its clinical workforce. Coordinating healthcare across clinicians, devices, rooms and shifts in constant motion is a challenge, with no single AI tool able to keep pace with the complexity of an operational hospital. Agentic AI represents a new hospital operating system that is adaptive, orchestrated and built to scale clinical expertise, extending Taiwan's healthcare workforce capacity to serve the population's growing demands. More... |
| AI repurposes routine chest X-rays to catch silent bone loss before fracture Press release 30 May, 2026 Osteoporosis is a silent disease where bone loss develops gradually before fractures occur. Current clinical screening recommendations mainly focus on older women and selected high-risk groups, leaving some men, younger adults, and individuals with normal body weight completely outside routine screening pathways. To close this care gap, researchers from St. Paul's Hospital and National Taiwan University have demonstrated how AI can leverage routine chest X-rays to detect asymptomatic bone loss, closing critical gaps in screening healthy Asian populations. Their paper is published in the journal npj Digital Medicine. More... |
| Biotech community mourns the passing of Samuel Yin Press release 27 May, 2026 The local biotech community mourns the passing of Samuel Yin, one of Taiwan's most influential philanthropists and biotech advocates. Yin provided major support to higher education, biomedical research, healthcare, and innovation, donating extensively to institutions including National Tsing Hua University, National Yang Ming Chiao Tung University, National Chengchi University, Academia Sinica. He also helped establish Taiwan's first heavy ion cancer therapy center at Taipei Veterans General Hospital through a NT$1.5 billion contribution and ensuring that 2% of treatments would be provided free to underprivileged patients. He later donated more than NT$2.1 billion for a new hospital staff dormitory. Yin supported pioneering biotech entrepreneurs, fostered international collaborations, and built a business presence spanning drug development, CRO services, venture investment, and healthcare distribution. His contributions also included funding the Samuel C. C. Ting Biomedical Research Laboratory at Scripps Research and donating NT$2 billion to the NHRI during the COVID-19 pandemic to support vaccine development. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |